Modulation by Interferon Alpha of the Decreased Natural Killer Activity in Patients with Glioblastoma

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 1991 Jan 1

PMID 1858528

Authors

P Lapena

C Isasi

J Vaquero

R Martinez

M Alvarez-Mon

Affiliations

Soon will be listed here.

Abstract

It is known that natural killer (NK) cells are involved in immunosurveillance against tumours. This study examines the NK activity of mononuclear cells (MNC) from the peripheral blood of patients with glioblastoma. The cytotoxic inducer effect of interferon-alpha (IFN-alpha) upon these MNC has also been studied. A marked decrease in NK activity mediated by MNC from these patients was found. This functional defected in MNC is not due to a decrease in phenotypically defined NK cells. After long-term (5-day) incubation with IFN-alpha, MNC from 5 out of 14 patients showed strong lytic activity against NK-sensitive target cells. In this system, IFN-alpha failed to induce cytotoxic activity against NK-resistant target cells in MNC from all the patients studied. This in vitro induction of cytotoxic activity in MNC from some patients with glioblastoma by IFN-alpha suggests a potential immunotherapeutic use of the lymphokine in these subjects.

References

de la Hera A, Alvarez-Mon M, Sanchez-Madrid F, Martinez C, Durantez A . Co-expression of Mac-1 and p150,95 on CD5+ B cells. Structural and functional characterization in a human chronic lymphocytic leukemia. Eur J Immunol. 1988; 18(7):1131-4. DOI: 10.1002/eji.1830180725. View

Barlozzari T, Leonhardt J, Wiltrout R, Herberman R, Reynolds C . Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol. 1985; 134(4):2783-9. View

Braun D, Penn R, Harris J . Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies. Neurosurgery. 1984; 15(1):29-33. DOI: 10.1227/00006123-198407000-00007. View

Boyum A . Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 1968; 97:7. View

Vaquero J, Martinez R, Oya S, Coca S, Barbolla L, Ramiro J . Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma. Acta Neurochir (Wien). 1989; 98(1-2):35-41. DOI: 10.1007/BF01407174. View

Carballido J, Alvarez-Mon M, Solovera O, Durantez A . Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol. 1990; 143(1):29-33. DOI: 10.1016/s0022-5347(17)39854-3. View

Walker M, ALEXANDER Jr E, HUNT W, MacCARTY C, MAHALEY Jr M, Mealey Jr J . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49(3):333-43. DOI: 10.3171/jns.1978.49.3.0333. View

Alvarez-Mon M, Casas J, Laguna R, Jorda J, Durantez A . Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia. Eur J Haematol. 1987; 38(3):268-73. DOI: 10.1111/j.1600-0609.1987.tb01175.x. View

Kadish A, Doyle A, Steinhauer E, GHOSSEIN N . Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol. 1981; 127(5):1817-22. View

10.

Timonen T, Ortaldo J, Herberman R . Analysis by a single cell cytotoxicity assay of natural killer (NK) cells frequencies among human large granular lymphocytes and of the effects of interferon on their activity. J Immunol. 1982; 128(6):2514-21. View

11.

Itoh K, Tilden A, Balch C . Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol. 1986; 136(10):3910-5. View

12.

Herberman R, Ortaldo J . Natural killer cells: their roles in defenses against disease. Science. 1981; 214(4516):24-30. DOI: 10.1126/science.7025208. View

13.

Lanier L, Le A, Phillips J, Warner N, Babcock G . Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983; 131(4):1789-96. View